本文へ移動
cccskills
無料GitHub で公開

es-male-sexual-dev-testis-avoid

This skill determines whether testicular volume should be used as the primary or sole indicator of sexual development in male childhood cancer survivors who have received gonadotoxic treatments such as alkylating agents or testicular radiotherapy. Triggers include clinician questions like “Can I use testicular volume to assess puberty in this male survivor after chemotherapy?” or “Is testis size reliable for sexual maturity evaluation post‑radiation?”

dromlakhani/MD2SKILL
インストール方法を見る

含まれるファイル（1）

  • SKILL.md2.8 KB

SKILL.md（原文）

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Avoid testicular volume for sexual staging post-gonadotoxic therapy

STEP 1 — Gather Information

Confirm patient is a male childhood cancer survivor with history of gonadotoxic therapy (alkylating agents, testicular radiotherapy, or similar). Collect clinical pubertal assessment (Tanner staging), serum testosterone (preferably LC‑MS/MS), luteinizing hormone (LH) levels drawn before 10:00 AM, and relevant treatment details (dose, timing).

STEP 2 — Rule In / Rule Out

Is the patient a male childhood cancer survivor previously exposed to gonadotoxic agents?

  • Yes → proceed to Step 3 (testicular volume unreliable).
  • No → testicular volume may be used per standard pubertal staging; no further action needed by this skill.

STEP 3 — Classify or Stratify

Classify that testicular volume is not a reliable primary or sole indicator of sexual maturation due to gonadotoxic injury to germ cells and Sertoli cells; rely instead on hormonal and clinical markers.

STEP 4 — Decide

Decide to assess sexual development using serum testosterone and LH levels in conjunction with clinical examination (e.g., Tanner staging), rather than testicular volume alone, to guide decisions about pubertal status and potential hormone replacement.

Clinical Guardrails / Mimics / Pitfalls

Do not rely solely on testicular volume; reduced testis size may reflect germinal epithelium injury rather than central pubertal status. Elevated LH in this context often indicates primary gonadal injury, not onset of central puberty. Avoid misinterpreting prepubertal testicular volume as delayed central puberty without hormonal correlation.

Concrete Clinical Example

A 14‑year‑old male survivor of acute lymphoblastic leukemia treated with cyclophosphamide and testicular radiotherapy presents with absent pubertal changes. Testicular volume is 3 mL (prepubertal range). Serum testosterone is low and LH is markedly elevated, indicating primary gonadal injury. Using testicular volume alone would suggest delayed puberty; the correct interpretation is gonadal failure, leading to consideration of testosterone replacement after further evaluation.

Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, DOI:10.1210/jc.2018-01175

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

ログインしてレビューを書く

同じリポジトリのスキル

概要と使いどころ

780g-pump-adjustment

無料

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-acth-stim-test-interpretation

無料

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-adrenal-crisis-treatment

無料

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-ai-education

無料

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-lt4-monitoring

無料

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-cortisol-cutoff-ai-diagnosis

無料

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する